Is a Surprise Coming for Exact Sciences (EXAS) This Earnings Season?Zacks Investment Research • 10/29/21
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/26/21
New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) ScreeningPRNewsWire • 10/25/21
This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And GileadBenzinga • 09/06/21
Why Is Exact Sciences (EXAS) Down 9.4% Since Last Earnings Report?Zacks Investment Research • 08/27/21
Exact Sciences receives regulatory approval for the Oncotype DX Breast Recurrence Score® Program in JapanPRNewsWire • 08/16/21
Clinical Gastroenterology and Hepatology Publishes Data Showing Exact Sciences' Oncoguard™ Liver Liquid Biopsy Test Delivers Enhanced Performance for Early-stage Detection of Hepatocellular CarcinomaPRNewsWire • 08/13/21
Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/29/21
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/21/21
Tuesday Analyst Upgrades and Downgrades: Campbell Soup, Exact Sciences, Exelixis, Spirit Airlines, Sarepta, ZTO and More24/7 Wall Street • 06/15/21
Exact Sciences (EXAS) Down 1.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/03/21